Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10365425" target="_blank" >RIV/00216208:11110/17:10365425 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/17:10365425

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s11096-017-0522-7" target="_blank" >http://dx.doi.org/10.1007/s11096-017-0522-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s11096-017-0522-7" target="_blank" >10.1007/s11096-017-0522-7</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation

Popis výsledku v původním jazyce

Background: Although measurement of drug serum levels is an objective direct method for testing compliance, it can be distorted by &quot;white-coat compliance&quot; or by variations in drug elimination. Objective: The aim of this prospective study was to evaluate the prevalence of noncompliance with perindopril therapy in adult out-patients using pharmacokinetic simulations. The additional aim was to compare the predictive performance of two glomerular filtration rate markers-creatinine and cystatin C. Setting: Department of Cardiology, Tomas Bata Regional Hospital in Zlin, Czech Republic. Method: Perindoprilat pharmacokinetic models individualized according to patient characteristics were compared with measured perindoprilat serum concentrations to document compliance. Linear regression was used to evaluate the relations between perindoprilat clearance and glomerular filtration rate estimated using creatinine and cystatin C. Main outcome measure: Assessment of non-compliance with medication using drug concentration measurements reinforced with therapeutic drug monitoring. Results: Non-detectable perindoprilat levels were observed in 26.1% of patients. Another 21.7% were classified as non-compliant based on therapeutic drug monitoring pharmacokinetic simulations. Volume of distribution, clearance and half-life median value (interquartiA degrees range) for perindoprilat were 408.3 (360.4-456.8) L, 10.1 (4.9-17.0) L h(-1) and 24.7 (19.4-62.7) h, respectively. Linear regression models showed tight relationship between cystatin C and perindoprilat clearance. Conclusions: Assessment of adherence with medication reinforced with therapeutic drug monitoring and pharmacokinetic simulations is proposed as an optimal method reducing disadvantages of simple drug concentration measurements. Cystatin C proves to be better surrogate marker for perindoprilat elimination than creatinine.

Název v anglickém jazyce

Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation

Popis výsledku anglicky

Background: Although measurement of drug serum levels is an objective direct method for testing compliance, it can be distorted by &quot;white-coat compliance&quot; or by variations in drug elimination. Objective: The aim of this prospective study was to evaluate the prevalence of noncompliance with perindopril therapy in adult out-patients using pharmacokinetic simulations. The additional aim was to compare the predictive performance of two glomerular filtration rate markers-creatinine and cystatin C. Setting: Department of Cardiology, Tomas Bata Regional Hospital in Zlin, Czech Republic. Method: Perindoprilat pharmacokinetic models individualized according to patient characteristics were compared with measured perindoprilat serum concentrations to document compliance. Linear regression was used to evaluate the relations between perindoprilat clearance and glomerular filtration rate estimated using creatinine and cystatin C. Main outcome measure: Assessment of non-compliance with medication using drug concentration measurements reinforced with therapeutic drug monitoring. Results: Non-detectable perindoprilat levels were observed in 26.1% of patients. Another 21.7% were classified as non-compliant based on therapeutic drug monitoring pharmacokinetic simulations. Volume of distribution, clearance and half-life median value (interquartiA degrees range) for perindoprilat were 408.3 (360.4-456.8) L, 10.1 (4.9-17.0) L h(-1) and 24.7 (19.4-62.7) h, respectively. Linear regression models showed tight relationship between cystatin C and perindoprilat clearance. Conclusions: Assessment of adherence with medication reinforced with therapeutic drug monitoring and pharmacokinetic simulations is proposed as an optimal method reducing disadvantages of simple drug concentration measurements. Cystatin C proves to be better surrogate marker for perindoprilat elimination than creatinine.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Clinical Pharmacy

ISSN

2210-7703

e-ISSN

—

Svazek periodika

39

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

6

Strana od-do

1095-1100

Kód UT WoS článku

000415360600017

EID výsledku v databázi Scopus

2-s2.0-85027016372